Resveratrol pretreatment protects rat hearts from ischemia/reperfusion injury partly via a NALP3 inflammasome pathway

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 8, 2015, Pages 8731-8741

  Dong, Wusong ^a   Yang, Rui ^b,c   Yang, Jian ^a   Yang, Jun ^a   Ding, Jiawang ^a   Wu, Hui ^a   Zhang, Jing ^a  

^a CHINA THREE GORGES UNIVERSITY   (China)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Caspase1; I R injury; Inflammasome body; NALP3; Resveratrol

Indexed keywords

ANTIOXIDANT; CARRIER PROTEIN; CRYOPYRIN; INFLAMMASOME; MESSENGER RNA; NLRP3 PROTEIN, RAT; RESVERATROL; STILBENE DERIVATIVE;

ANIMAL; CARDIAC MUSCLE; DISEASE MODEL; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART; MALE; METABOLISM; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; PATHOLOGY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

ANIMALS; ANTIOXIDANTS; BLOTTING, WESTERN; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEART; INFLAMMASOMES; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STILBENES;

EID: 85012991790     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Prasad A, Stone GW, Holmes DR, Gersh B. Reperfusion injury, microvascular dysfunction, and cardioprotection: the "dark side" of reperfusion. Circulation 2009; 120: 2105-12.
2. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002; 53: 31-47.
3. Steffens S, Montecucco F, Mach F. The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. Thromb Haemost 2009; 102: 240-247.
4. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121-1135.
5. Litt MR, Jeremy RW, Weisman HF, Winkelstein JA, Becker LC. Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia: Evidence for neutrophil-mediated reperfusion injury. Circulation 1989; 80: 1816-1827.
6. Ma XL, Tsao PS, Lefer AM. Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion. J Clin Invest 1991; 88: 1237-1243.
7. Zhao ZQ, Lefer DJ, Sato H, Hart KK, Jefforda PR, Vinten-Johansen J. Monoclonal antibody to ICAM-1 preserves postischemic blood flow and reduces infarct size after ischemia-reperfusion in rabbit. J Leukoc Biol 1997; 62: 292-300.
8. Cassel SL, Eisenbarth SC, Iyer SS, Sadler JJ, Colegio OR, Tephly LA, Carter AB, Rothman PB, Flavell RA, Sutterwala FS. The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci U S A 2008; 105: 9035-9040.
9. Chen GY, Nunez G. Sterile inflammation: Sensing and reacting to damage. Nat Rev Immunol 2010; 10: 826-837.
10. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008; 320: 674-677.
11. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nuñez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464: 1357-1361.
12. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz E, Moore KJ, Golenbock DT. The NALP3 inflam masome is involved in the innate immune response to amyloidbeta. Nat Immunol 2008; 9: 857-865.
13. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, Becker C, Franchi L, Yoshihara E, Chen Z, Mullooly N, Mielke LA, Harris J, Coll RC, Mills KH, Mok KH, Newsholme P, Nuñez G, Yodoi J, Kahn SE, Lavelle EC, O'Neill LA. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1 beta in type 2 diabetes. Nat Immunol 2010; 11: 897-904.
14. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010; 11: 136-140.
15. Davis BK, Wen H, Ting JP. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 2011; 29: 707-735.
16. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009; 27: 229-265.
17. Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol 2009; 7: 99-109
18. Pomerantz BJ, Reznikov LL, Harken AH, Dinarello CA. Inhibition of caspase1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci U S A 2001; 98: 2871-2876.
19. Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H, Izawa A, Takahashi Y, Masumoto J, Koyama J, Hongo M, Noda T, Nakayama J, Sagara J, Taniguchi S, Ikeda U. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 2011; 123: 594-604.
20. Zhu P, Duan L, Chen J, Xiong A, Xu Q, Zhang H, Zheng F, Tan Z, Gong F, Fang M. Gene silencing of NALP3 protects against liver ischemia-reperfusion injury in mice. Hum Gene Ther 2011; 22: 853-864.
21. Liu J, Yi L, Xiang Z, Zhong J, Zhang H, Sun T. Resveratrol attenuates spinal cord injury-induced inflammatory damage in rat lungs. Int J Clin Exp Pathol 2015; 8: 1237-1246.
22. Rubbo H, Trostchansky A, Botti H. Interaction of nitric oxide and peroxinitrite with low density lipoprotein. Biol Chem 2002; 383: 547-552.
23. Zou JG, Wang ZR, Huang YZ. Effect of red wine and wine polyphenol resveratrol on endothelial function in hypercholesterolemic rabbits. Int J Mol Med 2003; 11: 317-320.
24. Liu JC, Chen JJ, Chan P. Inhibition of cyclic strain-induced endothelin-1 gene expression by resveratrol. Hypertension 2003; 42: 1198-1205.
25. Arichi H, Kimura Y, Okuda H, Bana K, Kozawa M, Arichi S. Effects of stilbene components of the roots of polygonum on lipid metabolism. Chem Pharm Bull 1982; 30: 1766-1770.
26. Leighton F, Cuevas A, Guasch V. Plasma polyphenols and anti-oxidants, oxidative DNA damage and endothelial function in diet and wine intervention study in humans. Drugs Exp Clin Res 1999; 25: 133-141.
27. Bertelli AA, Giovannini L, Giannessi D, Migliori M, Bernini W, Fregoni M, Bertelli A. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int J Tissue React 1995; 17: 1-3.
28. Godichaud S, Krisa S, Couronne B. Deactivation of cultured human liver myofibroblasys by trans-resveratrol, a grape vine-derived polyphenol. Hepatology 2000; 31: 922-931.
29. Wang Z, You J, Huang Y. Effect of resveratrol on platelet aggregation in vivo and in vitro. Chin Med J (Engl) 2002; 115: 378-380.
30. Olas B, Wachowicz B, Saluk-Juszezak J. Effect of resveratrol, a natural polyphenolic compound, on platelet activation induced by endotoxin or thrombin. Thromb Res 2002; 107: 141-145.
31. Jayatilake GS, Jayasuriya H, Lee ES, Koonchanok NM, Geahlen RL, Ashendel CL, McLaughlin JL, Chang CJ. Kinase inhibitors polygonum cuspidatum. J Nat Prod 1993; 56: 1805-1810.
32. Jang M, Pezzuto JM. Cancer chemopreventive activity of resveratrol. Drug Exp Clin Res 1999; 25: 65-77.
33. Cao Z, Li Y. Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury. Eur J Pharmacol 2004; 489: 39-48.
34. Hung LM, Chen JK, Huang SS, Lee RS, Su MJ. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc Res 2000; 47: 549-555.
35. Hung LM, Chen JK, Lee RS, Liang HC, Su MJ. Beneficial effects of astringinin, a resveratrol analogue, on the ischemia and reperfusion damage in rat heart. Free Radic Biol Med 2001; 30: 877-883.
36. Maulik N, Engelman RM, Rousou JA, Flack JE 3rd, Deaton D, Das DK. Ischemic preconditioning reduces apoptosis by upregulating anti-death gene Bcl-2. Circulation 1999; 100: II369-II375.
37. Pinteaux E, Rothwell N, Boutin H. Neuroprotective actions ojendogenous interleukin-1 receptor antagonist (IL-1 ra) are mediated by glia. Glia 2006; 53: pp. 551-6.
38. Valtchanova-Matchouganska A, Gondwe M, Nadar A. The role of C-reactive protein in ischemia/reperfusion injury and preconditioning in a rat model of myocardial infarction. Life Sci 2004; 75: 901-910.
39. Du Y, Ko KM. Oleanolic acid protects against myocardial ischemia-reperfusion injury by enhancing mitochondrial antioxidant mechanism mediated by glutathione and alpha-tocopherol in rats. Planta Med 2006; 2: 222-227.
40. Robinet A, Millart H, Oszust F, Hornebeck W, Bellon G. Binding of elastin peptides to S-Gal protects the heart against ischemia/reperfusion injury by triggering the RISK pathway. FASEB J 2007; 21: 1968-1978.
41. Prasad A, Stone GW, Holmes DR, Gersh B. Reperfusion injury, microvascular dysfunction, and cardioprotection: the "dark side" of reperfusion. Circulation 2009; 120: 2105-12.
42. Steffens S, Montecucco F, Mach F. The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. Thromb Haemost 2009; 102: 240-7.
43. Yang D, Yuan W, Lv C, Li N, Liu T, Wang L, Sun Y, Qiu X, Fu Q. Dihydroartemisinin supresses inflammation and fibrosis in bleomycine-induced pulmonary fibrosis in rats. Int J Clin Exp Pathol 2015; 8: 1270-1281.
44. Kelly RA, Smith TW. Cytokines and cardiac contractile function. Circulation 1997; 95: 778-781.
45. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-241.